ruxolitinib Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 4190 941678-49-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ruxolitinib
  • jakafi
  • INCB 018424
  • ruxolitinib phosphate
  • jakavi
a kinase inhibitor, inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function
  • Molecular weight: 306.37
  • Formula: C17H18N6
  • CLOGP: 2.22
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 1
  • TPSA: 83.18
  • ALOGS: -3.42
  • ROTB: 4

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 16, 2011 FDA INCYTE CORP

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Platelet count decreased 3224.09 38.01 1030 13750 33972 4590240
Anaemia 3016.42 38.01 1176 13604 70384 4553828
Haemoglobin decreased 2979.73 38.01 988 13792 36669 4587543
Myelofibrosis 2581.77 38.01 453 14327 686 4623526
Splenomegaly 2433.76 38.01 532 14248 3608 4620604
Death 2421.65 38.01 1382 13398 196781 4427431
Fatigue 1873.10 38.01 1054 13726 144512 4479700
Platelet count increased 1798.34 38.01 418 14362 3842 4620370
Off label use 1501.48 38.01 877 13903 128236 4495976
Product dose omission 1476.22 38.01 699 14081 66263 4557949
White blood cell count increased 1474.83 38.01 468 14312 14799 4609413
Pneumonia 1273.97 38.01 729 14051 102086 4522126
Blood count abnormal 1201.99 38.01 299 14481 3732 4620480
Weight increased 1195.52 38.01 504 14276 36077 4588135
Thrombocytopenia 1079.76 38.01 508 14272 47165 4577047
Contusion 1010.15 38.01 374 14406 18884 4605328
Second primary malignancy 950.23 38.01 231 14549 2597 4621615
Acute myeloid leukaemia 891.11 38.01 266 14514 6779 4617433
Dizziness 871.63 38.01 567 14213 99304 4524908
Red blood cell count decreased 864.77 38.01 270 14510 8033 4616179
Diarrhoea 828.29 38.01 644 14136 149541 4474671
Pyrexia 823.30 38.01 562 14218 106582 4517630
Dyspnoea 781.16 38.01 603 14177 138382 4485830
Product use in unapproved indication 770.45 38.01 332 14448 24941 4599271
Asthenia 770.23 38.01 497 14283 85666 4538546
Headache 724.53 38.01 548 14232 121825 4502387
Primary myelofibrosis 598.74 38.01 95 14685 34 4624178
Malaise 579.99 38.01 425 14355 89732 4534480
White blood cell count decreased 566.59 38.01 292 14488 32773 4591439
Haematocrit decreased 565.76 38.01 200 14580 8782 4615430
Night sweats 520.76 38.01 171 14609 5980 4618232
Epistaxis 513.94 38.01 232 14548 19411 4604801
Abdominal pain 485.70 38.01 326 14454 59698 4564514
Fall 474.66 38.01 356 14424 77690 4546522
Herpes zoster 452.15 38.01 199 14581 15664 4608548
Abdominal distension 440.66 38.01 203 14577 17786 4606426
Blast cell count increased 436.47 38.01 86 14694 313 4623899
Flatulence 417.78 38.01 156 14624 8008 4616204
Infection 406.50 38.01 242 14538 35900 4588312
Blood lactate dehydrogenase increased 395.32 38.01 147 14633 7456 4616756
Weight decreased 391.14 38.01 275 14505 54189 4570023
Nausea 385.41 38.01 456 14324 176877 4447335
Muscle spasms 381.90 38.01 231 14549 35259 4588953
Cough 369.98 38.01 268 14512 55319 4568893
Constipation 362.41 38.01 238 14542 41916 4582296
Haemorrhage 350.96 38.01 195 14585 25367 4598845
Leukocytosis 344.13 38.01 133 14647 7501 4616711
Sepsis 342.03 38.01 231 14549 42608 4581604
Urinary tract infection 337.05 38.01 228 14552 42162 4582050
Increased appetite 333.54 38.01 100 14680 2573 4621639
Pain in extremity 333.01 38.01 266 14514 63473 4560739
Bone pain 329.53 38.01 152 14628 13334 4610878
Leukaemia 328.21 38.01 91 14689 1757 4622455
Abdominal discomfort 326.52 38.01 193 14587 28215 4595997
Decreased appetite 317.47 38.01 246 14534 56151 4568061
Pain 314.96 38.01 303 14477 92567 4531645
Pancytopenia 309.80 38.01 178 14602 24675 4599537
Oedema peripheral 303.56 38.01 213 14567 41759 4582453
Nasopharyngitis 292.21 38.01 191 14589 33326 4590886
Pruritus 286.85 38.01 258 14522 72314 4551898
Cardiac failure 286.63 38.01 175 14605 27113 4597099
Peripheral swelling 274.78 38.01 169 14611 26523 4597689
Polycythaemia vera 271.32 38.01 53 14727 182 4624030
Arthralgia 271.20 38.01 264 14516 81730 4542482
Concomitant disease aggravated 264.75 38.01 78 14702 1885 4622327
Blood creatinine increased 260.92 38.01 164 14616 26736 4597476
Influenza 259.74 38.01 149 14631 20574 4603638
Transformation to acute myeloid leukaemia 257.91 38.01 48 14732 117 4624095
Acute leukaemia 253.17 38.01 62 14718 716 4623496
Back pain 253.08 38.01 206 14574 50393 4573819
Squamous cell carcinoma 246.86 38.01 86 14694 3601 4620611
Incorrect dose administered 241.91 38.01 139 14641 19246 4604966
Haematoma 236.66 38.01 110 14670 9806 4614406
Gout 236.22 38.01 87 14693 4286 4619926
Cytopenia 231.87 38.01 74 14706 2352 4621860
General physical health deterioration 231.40 38.01 156 14624 28622 4595590
Memory impairment 230.06 38.01 137 14643 20266 4603946
Tuberculosis 214.93 38.01 82 14698 4457 4619755
Platelet count abnormal 214.14 38.01 62 14718 1406 4622806
Skin cancer 213.69 38.01 76 14704 3383 4620829
Vomiting 211.23 38.01 278 14502 119421 4504791
Basal cell carcinoma 204.10 38.01 84 14696 5580 4618632
Bone marrow failure 201.97 38.01 107 14673 12631 4611581
Insomnia 198.48 38.01 171 14609 45174 4579038
Rash 196.23 38.01 255 14525 108133 4516079
Abdominal pain upper 190.41 38.01 150 14630 34965 4589247
Graft versus host disease in gastrointestinal tract 189.72 38.01 50 14730 789 4623423
Therapeutic response unexpected 184.68 38.01 83 14697 6839 4617373
Feeling abnormal 181.41 38.01 148 14632 36257 4587955
Respiratory failure 180.67 38.01 137 14643 30189 4594023
Lymphocyte count decreased 175.57 38.01 77 14703 5986 4618226
Thrombocytosis 174.42 38.01 55 14725 1679 4622533
Skin lesion 171.79 38.01 81 14699 7452 4616760
Ascites 169.60 38.01 94 14686 12131 4612081
Febrile neutropenia 168.16 38.01 124 14656 26188 4598024
Renal impairment 165.52 38.01 121 14659 25217 4598995
Iron overload 165.13 38.01 38 14742 328 4623884
Blood uric acid increased 163.05 38.01 53 14727 1787 4622425
Alopecia 160.97 38.01 124 14656 27956 4596256
Chills 160.21 38.01 125 14655 28714 4595498
Blood potassium increased 158.27 38.01 68 14712 5027 4619185
Drug ineffective 157.36 38.01 309 14471 185752 4438460
Transfusion 157.12 38.01 60 14720 3267 4620945
Haematocrit increased 156.75 38.01 40 14740 552 4623660
Blood urea increased 151.53 38.01 78 14702 8672 4615540
Neutrophil count increased 148.19 38.01 64 14716 4791 4619421
Pollakiuria 148.04 38.01 72 14708 7093 4617119
Dyspnoea exertional 148.02 38.01 81 14699 10191 4614021
Pleural effusion 147.00 38.01 111 14669 24287 4599925
Hepatic function abnormal 144.85 38.01 90 14690 14346 4609866
Red blood cell count increased 139.49 38.01 37 14743 599 4623613
Disease progression 138.90 38.01 134 14646 40877 4583335
Bronchitis 138.38 38.01 99 14681 19941 4604271
Myeloproliferative neoplasm 136.12 38.01 32 14748 306 4623906
Graft versus host disease 135.70 38.01 54 14726 3284 4620928
Hepatomegaly 133.49 38.01 55 14725 3660 4620552
Serum ferritin increased 131.01 38.01 45 14735 1803 4622409
Renal failure 124.94 38.01 127 14653 41242 4582970
Stomatitis 123.68 38.01 86 14694 16553 4607659
Oropharyngeal pain 122.89 38.01 87 14693 17232 4606980
Gait disturbance 122.70 38.01 119 14661 36521 4587691
Dehydration 122.60 38.01 127 14653 42163 4582049
Gastrointestinal haemorrhage 119.19 38.01 108 14672 30427 4593785
Blood alkaline phosphatase increased 117.99 38.01 75 14705 12432 4611780
Splenic infarction 110.82 38.01 32 14748 718 4623494
Hypertension 110.07 38.01 131 14649 50667 4573545
Neutropenia 109.45 38.01 127 14653 47823 4576389
Myalgia 108.99 38.01 119 14661 41929 4582283
C-reactive protein increased 108.99 38.01 72 14708 12740 4611472
Hypoaesthesia 108.18 38.01 104 14676 31561 4592651
Therapy non-responder 108.15 38.01 78 14702 15899 4608313
Increased tendency to bruise 105.80 38.01 41 14739 2322 4621890
Cellulitis 104.92 38.01 78 14702 16654 4607558
Blast cells present 104.56 38.01 23 14757 158 4624054
Basophil count increased 104.30 38.01 24 14756 207 4624005
Acute kidney injury 103.46 38.01 150 14630 70281 4553931
Red cell distribution width increased 103.35 38.01 33 14747 1049 4623163
Somnolence 100.23 38.01 116 14664 43544 4580668
Atrial fibrillation 100.04 38.01 99 14681 31116 4593096
Muscular weakness 99.88 38.01 92 14688 26458 4597754
Acne 99.49 38.01 50 14730 5282 4618930
Gamma-glutamyltransferase increased 97.56 38.01 64 14716 11190 4613022
Dry mouth 95.68 38.01 67 14713 13034 4611178
Cystitis 94.86 38.01 54 14726 7326 4616886
Hyperhidrosis 94.24 38.01 94 14686 29823 4594389
Cardiac failure congestive 93.82 38.01 98 14682 32824 4591388
Dysphagia 93.19 38.01 87 14693 25444 4598768
Aspartate aminotransferase increased 93.00 38.01 86 14694 24852 4599360
Therapeutic response decreased 92.02 38.01 68 14712 14383 4609829
Blood iron decreased 91.83 38.01 35 14745 1894 4622318
Septic shock 91.59 38.01 72 14708 16694 4607518
Neuropathy peripheral 90.94 38.01 83 14697 23586 4600626
Red blood cell count abnormal 90.78 38.01 22 14758 242 4623970
Oesophageal varices haemorrhage 89.85 38.01 29 14751 955 4623257
Varices oesophageal 89.20 38.01 30 14750 1126 4623086
Skin discolouration 89.06 38.01 55 14725 8663 4615549
Hospitalisation 88.86 38.01 93 14687 31212 4593000
Spleen disorder 88.09 38.01 24 14756 432 4623780
Early satiety 87.99 38.01 22 14758 278 4623934
Thrombosis 87.76 38.01 73 14707 18331 4605881
Chest pain 86.38 38.01 116 14664 50584 4573628
Sinusitis 86.00 38.01 79 14701 22633 4601579
Leukopenia 85.02 38.01 77 14703 21659 4602553
Blood pressure increased 84.48 38.01 88 14692 29372 4594840
Liver disorder 84.22 38.01 62 14718 13036 4611176
Squamous cell carcinoma of skin 83.97 38.01 34 14746 2162 4622050
Vision blurred 83.82 38.01 81 14699 24722 4599490
Musculoskeletal pain 83.71 38.01 68 14712 16520 4607692
Balance disorder 82.79 38.01 67 14713 16189 4608023
Joint swelling 82.06 38.01 79 14701 23999 4600213
Oral herpes 81.45 38.01 37 14743 3121 4621091
Dyspepsia 81.41 38.01 66 14714 15988 4608224
Hyperuricaemia 80.39 38.01 31 14749 1732 4622480
Blood glucose increased 79.83 38.01 78 14702 24126 4600086
Glomerular filtration rate decreased 79.62 38.01 37 14743 3289 4620923
Upper respiratory tract infection 79.19 38.01 61 14719 13726 4610486
Haemoglobin abnormal 78.43 38.01 29 14751 1442 4622770
Alanine aminotransferase increased 78.22 38.01 83 14697 28290 4595922
Respiratory tract infection 77.46 38.01 47 14733 7173 4617039
Blood iron increased 77.07 38.01 22 14758 473 4623739
Bronchopulmonary aspergillosis 76.97 38.01 35 14745 2959 4621253
Nocardiosis 75.72 38.01 25 14755 885 4623327
Pulmonary hypertension 74.95 38.01 49 14731 8514 4615698
Nephrolithiasis 74.94 38.01 50 14730 8989 4615223
Haematemesis 74.92 38.01 50 14730 8993 4615219
Dysuria 74.90 38.01 48 14732 8062 4616150
Skin ulcer 74.55 38.01 46 14734 7232 4616980
Visual impairment 74.27 38.01 68 14712 19392 4604820
Blood pressure systolic increased 73.40 38.01 38 14742 4270 4619942
Neutrophil count decreased 72.94 38.01 58 14722 13665 4610547
Diffuse large B-cell lymphoma 72.92 38.01 31 14749 2230 4621982
Blood bilirubin increased 72.71 38.01 56 14724 12596 4611616
Chronic myeloid leukaemia 72.16 38.01 27 14753 1388 4622824
Arthritis 71.52 38.01 59 14721 14641 4609571
Cerebrovascular accident 71.37 38.01 96 14684 41904 4582308
Fluid retention 71.04 38.01 53 14727 11368 4612844
Renal disorder 70.82 38.01 49 14731 9347 4614865
Lung infiltration 70.03 38.01 38 14742 4696 4619516
Cerebral haemorrhage 69.71 38.01 56 14724 13385 4610827
Wrong technique in product usage process 69.66 38.01 85 14695 33689 4590523
Cardiac disorder 69.65 38.01 62 14718 17047 4607165
Anxiety 68.61 38.01 101 14679 47910 4576302
Multiple organ dysfunction syndrome 68.59 38.01 64 14716 18692 4605520
Blister 68.46 38.01 52 14728 11457 4612755
Splenectomy 67.99 38.01 19 14761 377 4623835
Full blood count decreased 67.12 38.01 41 14739 6331 4617881
Blast cell crisis 67.10 38.01 15 14765 112 4624100
Ecchymosis 66.49 38.01 31 14749 2776 4621436
Chronic obstructive pulmonary disease 66.35 38.01 55 14725 13739 4610473
Platelet disorder 66.30 38.01 21 14759 650 4623562
Inappropriate schedule of product administration 66.24 38.01 68 14712 22302 4601910
Haematochezia 65.84 38.01 50 14730 11014 4613198
Hepatosplenomegaly 65.08 38.01 24 14756 1184 4623028
Burning sensation 64.86 38.01 51 14729 11821 4612391
Oedema 64.78 38.01 62 14718 18689 4605523
Post procedural haemorrhage 63.81 38.01 31 14749 3042 4621170
White blood cell count abnormal 63.57 38.01 24 14756 1265 4622947
Haemoglobin increased 63.56 38.01 23 14757 1075 4623137
Mouth haemorrhage 62.44 38.01 27 14753 2025 4622187
Product use issue 61.61 38.01 69 14711 24967 4599245
Swelling 59.44 38.01 67 14713 24415 4599797
Viral infection 58.15 38.01 41 14739 8057 4616155
Iron deficiency 57.96 38.01 21 14759 985 4623227
Rhinorrhoea 57.88 38.01 48 14732 11994 4612218
Haemorrhagic diathesis 57.60 38.01 22 14758 1197 4623015
Graft versus host disease in liver 57.30 38.01 15 14765 230 4623982
Feeling cold 57.20 38.01 34 14746 4997 4619215
Melaena 57.05 38.01 44 14736 9914 4614298
Splenic rupture 56.90 38.01 19 14761 697 4623515
Impaired healing 56.45 38.01 41 14739 8438 4615774
Skin haemorrhage 56.28 38.01 25 14755 2000 4622212
Myelodysplastic syndrome 56.01 38.01 38 14742 7020 4617192
Depression 55.06 38.01 91 14689 47642 4576570
Leukaemic lymphoma 54.85 38.01 9 14771 6 4624206
Head injury 54.31 38.01 38 14742 7377 4616835
Hyperkalaemia 54.01 38.01 52 14728 15785 4608427
Hot flush 53.68 38.01 43 14737 10232 4613980
Lymphadenopathy 53.26 38.01 43 14737 10349 4613863
Paraesthesia 53.22 38.01 76 14704 35057 4589155
Myelocyte count increased 53.15 38.01 11 14769 54 4624158
Chronic leukaemia 52.72 38.01 10 14770 28 4624184
Interstitial lung disease 52.40 38.01 56 14724 19229 4604983
Blood product transfusion dependent 52.23 38.01 13 14767 161 4624051
Confusional state 52.21 38.01 90 14690 48744 4575468
Portal hypertension 51.82 38.01 21 14759 1338 4622874
Product administered to patient of inappropriate age 51.80 38.01 24 14756 2118 4622094
Acute graft versus host disease in skin 51.66 38.01 20 14760 1129 4623083
Pulmonary embolism 51.45 38.01 74 14706 34352 4589860
Pigmentation disorder 50.67 38.01 21 14759 1417 4622795
Blood pressure decreased 50.45 38.01 53 14727 17847 4606365
Medication error 50.42 38.01 48 14732 14368 4609844
Staphylococcal infection 50.12 38.01 42 14738 10646 4613566
Cryptococcosis 49.85 38.01 16 14764 517 4623695
Withdrawal syndrome 49.63 38.01 34 14746 6380 4617832
Dry skin 49.32 38.01 42 14738 10880 4613332
Diverticulitis 48.98 38.01 35 14745 7022 4617190
Rectal haemorrhage 48.93 38.01 44 14736 12252 4611960
Abscess 48.88 38.01 30 14750 4670 4619542
Mass 48.86 38.01 26 14754 3089 4621123
Palpitations 48.75 38.01 61 14719 24785 4599427
Musculoskeletal chest pain 48.75 38.01 28 14752 3860 4620352
Subdural haematoma 48.36 38.01 33 14747 6153 4618059
Extramedullary haemopoiesis 48.33 38.01 10 14770 49 4624163
Chronic kidney disease 48.20 38.01 41 14739 10604 4613608
Monocyte count increased 47.99 38.01 19 14761 1139 4623073
Graft versus host disease in skin 47.09 38.01 17 14763 789 4623423
Gastroenteritis viral 47.07 38.01 27 14753 3713 4620499
Splenic haemorrhage 46.66 38.01 12 14768 171 4624041
General physical condition abnormal 46.51 38.01 20 14760 1479 4622733
Haematocrit abnormal 46.28 38.01 13 14767 263 4623949
Lymphocyte count increased 46.27 38.01 18 14762 1029 4623183
Internal haemorrhage 45.90 38.01 19 14761 1278 4622934
Hip fracture 45.65 38.01 33 14747 6741 4617471
Vertigo 45.24 38.01 46 14734 14910 4609302
Gingival bleeding 45.20 38.01 26 14754 3595 4620617
Bacterial infection 44.16 38.01 28 14752 4615 4619597
Post herpetic neuralgia 43.87 38.01 14 14766 444 4623768
Mouth ulceration 43.84 38.01 31 14749 6119 4618093
Disseminated tuberculosis 43.69 38.01 18 14762 1196 4623016
Haemochromatosis 43.56 38.01 13 14767 328 4623884
Pulmonary oedema 43.35 38.01 45 14735 14941 4609271
Metamyelocyte count increased 43.18 38.01 9 14771 46 4624166
Pneumocystis jirovecii pneumonia 42.78 38.01 29 14751 5349 4618863
Jaundice 42.61 38.01 41 14739 12433 4611779
Concomitant disease progression 42.50 38.01 17 14763 1047 4623165
Cardiomegaly 42.38 38.01 28 14752 4949 4619263
Joint injury 42.35 38.01 25 14755 3627 4620585
Productive cough 42.10 38.01 36 14744 9377 4614835
Dysgeusia 41.97 38.01 44 14736 14775 4609437
Eating disorder 41.92 38.01 25 14755 3695 4620517
Haemoptysis 41.39 38.01 35 14745 8979 4615233
Haematuria 41.26 38.01 41 14739 12929 4611283
Lung disorder 41.02 38.01 40 14740 12331 4611881
Fungal infection 40.89 38.01 33 14747 7936 4616276
Chronic myelomonocytic leukaemia 40.13 38.01 12 14768 305 4623907
Escherichia urinary tract infection 40.01 38.01 19 14761 1772 4622440
Inflammation 39.69 38.01 36 14744 10135 4614077
Hypotension 39.62 38.01 97 14683 67303 4556909
Amnesia 39.55 38.01 40 14740 12881 4611331
Meningitis cryptococcal 39.32 38.01 14 14766 624 4623588
Acute graft versus host disease in intestine 39.25 38.01 14 14766 627 4623585
Blood disorder 38.94 38.01 19 14761 1882 4622330
Drug intolerance 38.90 38.01 51 14729 21695 4602517
Acute graft versus host disease in liver 38.49 38.01 12 14768 352 4623860
Skin disorder 38.33 38.01 29 14751 6347 4617865
Blood glucose decreased 38.22 38.01 28 14752 5837 4618375
Cholelithiasis 38.11 38.01 34 14746 9368 4614844

Pharmacologic Action:

SourceCodeDescription
ATC L01XE18 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Protein kinase inhibitors
FDA EPC N0000175605 Kinase Inhibitor
FDA MoA N0000175076 Protein Kinase Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Myelofibrosis indication 52967002 DOID:4971
Polycythemia vera indication 109992005
Myeloproliferative disorder indication 425333006
Coronavirus infection off-label use 186747009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.44 acidic
pKa2 4.6 Basic
pKa3 2.37 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 10MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 9079912 Dec. 12, 2026 USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2
EQ 10MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 9079912 Dec. 12, 2026 USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 10MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 9814722 Dec. 12, 2026 FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
EQ 15MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 9079912 Dec. 12, 2026 USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2
EQ 15MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 9079912 Dec. 12, 2026 USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 15MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 9814722 Dec. 12, 2026 FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
EQ 20MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 9079912 Dec. 12, 2026 USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2
EQ 20MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 9079912 Dec. 12, 2026 USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 20MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 9814722 Dec. 12, 2026 FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
EQ 25MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 9079912 Dec. 12, 2026 USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2
EQ 25MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 9079912 Dec. 12, 2026 USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 25MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 9814722 Dec. 12, 2026 FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
EQ 5MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 9079912 Dec. 12, 2026 USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2
EQ 5MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 9079912 Dec. 12, 2026 USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 5MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 9814722 Dec. 12, 2026 FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
EQ 10MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 7598257 Dec. 24, 2027 FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 10MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 7598257 Dec. 24, 2027 FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 15MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 7598257 Dec. 24, 2027 FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 15MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 7598257 Dec. 24, 2027 FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 20MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 7598257 Dec. 24, 2027 FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 20MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 7598257 Dec. 24, 2027 FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 25MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 7598257 Dec. 24, 2027 FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 25MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 7598257 Dec. 24, 2027 FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 5MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 7598257 Dec. 24, 2027 FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 5MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 7598257 Dec. 24, 2027 FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 10MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 10016429 June 12, 2028 FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
EQ 10MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 8822481 June 12, 2028 USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 10MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 8829013 June 12, 2028 FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 10MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 8829013 June 12, 2028 FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 15MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 10016429 June 12, 2028 FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
EQ 15MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 8822481 June 12, 2028 USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 15MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 8829013 June 12, 2028 FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 15MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 8829013 June 12, 2028 FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 20MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 10016429 June 12, 2028 FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
EQ 20MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 8822481 June 12, 2028 USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 20MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 8829013 June 12, 2028 FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 20MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 8829013 June 12, 2028 FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 25MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 10016429 June 12, 2028 FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
EQ 25MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 8822481 June 12, 2028 USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 25MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 8829013 June 12, 2028 FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 25MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 8829013 June 12, 2028 FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 5MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 10016429 June 12, 2028 FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
EQ 5MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 8822481 June 12, 2028 USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 5MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 8829013 June 12, 2028 FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 5MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL 8829013 June 12, 2028 FOR THE TREATMENT OF POLYCYTHEMIA VERA

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 10MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL Dec. 4, 2021 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 15MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL Dec. 4, 2021 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 20MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL Dec. 4, 2021 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 25MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL Dec. 4, 2021 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 5MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL Dec. 4, 2021 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 10MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2022 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 15MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2022 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 20MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2022 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 25MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2022 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 5MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2022 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 10MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2026 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 15MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2026 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 20MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2026 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 25MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2026 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 5MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2026 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Tyrosine-protein kinase JAK1 Kinase INHIBITOR Ki 10.05 CHEMBL CHEMBL
Tyrosine-protein kinase JAK2 Kinase INHIBITOR Kd 10.44 CHEMBL CHEMBL
Phosphatidylinositol 4-kinase beta Kinase Kd 5.47 CHEMBL
Serine/threonine-protein kinase DCLK1 Kinase Kd 7.17 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1 Kinase Kd 6.33 CHEMBL
SRSF protein kinase 1 Kinase Kd 5.68 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 2 Kinase Kd 5.43 CHEMBL
Serine/threonine-protein kinase RIO3 Kinase Kd 5.70 CHEMBL
Serine/threonine-protein kinase Nek3 Kinase Kd 5.96 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 3 Kinase Kd 6.33 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit beta Kinase Kd 6.51 CHEMBL
Ribosomal protein S6 kinase alpha-6 Kinase Kd 6.82 CHEMBL
Ribosomal protein S6 kinase alpha-1 Kinase Kd 6.92 CHEMBL
Cyclin-G-associated kinase Kinase Kd 7 CHEMBL
Serine/threonine-protein kinase SBK1 Kinase Kd 5.89 CHEMBL
Mitogen-activated protein kinase kinase kinase 15 Kinase Kd 5.96 CHEMBL
Microtubule-associated serine/threonine-protein kinase 1 Kinase Kd 6.28 CHEMBL
JAK2/TYK2 Kinase IC50 6.09 CHEMBL
JAK1/JAK2/TYK2 Kinase IC50 6.53 CHEMBL
JAK1/TYK2 Kinase IC50 6.71 CHEMBL
Homeodomain-interacting protein kinase 3 Kinase Kd 5.92 CHEMBL
Homeodomain-interacting protein kinase 2 Kinase Kd 6 CHEMBL
Maternal embryonic leucine zipper kinase Kinase Kd 5.66 CHEMBL
Serine/threonine-protein kinase PLK1 Kinase Kd 6.89 CHEMBL
Serine/threonine-protein kinase TBK1 Kinase Kd 5.77 CHEMBL
Serine/threonine-protein kinase Nek7 Kinase Kd 5.31 CHEMBL
Serine/threonine-protein kinase/endoribonuclease IRE1 Kinase Kd 5.60 CHEMBL
Serine/threonine-protein kinase B-raf Kinase Kd 5.66 CHEMBL
Serine/threonine-protein kinase OSR1 Kinase Kd 5.57 CHEMBL
STE20/SPS1-related proline-alanine-rich protein kinase Kinase Kd 5.72 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 6.14 CHEMBL
Dual specificity protein kinase CLK2 Kinase Kd 6.34 CHEMBL
G protein-coupled receptor kinase 7 Kinase Kd 6.27 CHEMBL
Homeodomain-interacting protein kinase 1 Kinase Kd 5.92 CHEMBL
JAK3/JAK1 Kinase IC50 7.64 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 6.32 CHEMBL
JAK2/JAK1 Kinase IC50 7.51 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 5.21 CHEMBL
Serine/threonine-protein kinase 16 Kinase Kd 6.31 CHEMBL
Serine/threonine-protein kinase 17B Kinase Kd 5.46 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit gamma Kinase Kd 7 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 6.70 CHEMBL
AP2-associated protein kinase 1 Kinase Kd 6.92 CHEMBL
Serine/threonine-protein kinase MARK2 Kinase Kd 6.18 CHEMBL
Protein kinase C epsilon type Kinase Kd 6.28 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 8.70 CHEMBL
Ribosomal protein S6 kinase alpha-5 Kinase Kd 6.85 CHEMBL
Casein kinase II subunit alpha' Kinase Kd 5.48 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 5.89 CHEMBL
Aurora kinase C Kinase Kd 5.06 CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase Kd 6 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 5.82 CHEMBL
Rho-associated protein kinase 1 Kinase Kd 7.22 CHEMBL
Ankyrin repeat and protein kinase domain-containing protein 1 Kinase Kd 6.41 CHEMBL
Serine/threonine-protein kinase 25 Kinase Kd 5.20 CHEMBL
Myosin light chain kinase, smooth muscle Kinase Kd 6.44 CHEMBL
Serine/threonine-protein kinase DCLK2 Kinase Kd 6.12 CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2 Kinase Kd 7.05 CHEMBL
Serine/threonine-protein kinase PAK 6 Kinase Kd 5.54 CHEMBL
Mast/stem cell growth factor receptor Kit Kinase Kd 5.20 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 6.68 CHEMBL
Serine/threonine-protein kinase PAK 7 Kinase Kd 5.89 CHEMBL
Serine/threonine-protein kinase 17A Kinase Kd 5.21 CHEMBL
Ribosomal protein S6 kinase alpha-4 Kinase Kd 6.47 CHEMBL
Dual specificity protein kinase CLK4 Kinase Kd 5.77 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2 Kinase Kd 6.70 CHEMBL
Death-associated protein kinase 2 Kinase Kd 7.01 CHEMBL
Bone morphogenetic protein receptor type-1B Kinase Kd 5.74 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Ki 9.30 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 6.54 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1D Kinase Kd 6.92 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1G Kinase Kd 5.66 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit beta Kinase Kd 5.64 CHEMBL
Serine/threonine-protein kinase TAO2 Kinase Kd 6.51 CHEMBL
Ribosomal protein S6 kinase alpha-2 Kinase Kd 6.82 CHEMBL
Serine/threonine-protein kinase ULK2 Kinase Kd 6.72 CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Kinase Kd 5.24 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 5.59 CHEMBL
Casein kinase II subunit alpha Kinase Kd 5.38 CHEMBL
NT-3 growth factor receptor Kinase Kd 6.48 CHEMBL
Rhodopsin kinase Kinase Kd 6.14 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit alpha Kinase Kd 7.34 CHEMBL
G protein-coupled receptor kinase 4 Kinase Kd 5.21 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 7.39 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 5.62 CHEMBL
Serine/threonine-protein kinase 26 Kinase Kd 5.51 CHEMBL
Serine/threonine-protein kinase PLK2 Kinase Kd 5.82 CHEMBL
Bone morphogenetic protein receptor type-2 Kinase Kd 6.03 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit epsilon Kinase Kd 5.92 CHEMBL
Peripheral plasma membrane protein CASK Kinase Kd 5.82 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 5.51 CHEMBL
Mitogen-activated protein kinase 8 Kinase Kd 5.32 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 6.23 CHEMBL
Casein kinase I isoform alpha Kinase Kd 5.74 CHEMBL
Mitogen-activated protein kinase kinase kinase 1 Kinase Kd 5.38 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 5.48 CHEMBL
Serine/threonine-protein kinase SIK3 Kinase Kd 5.89 CHEMBL
Rho-associated protein kinase 2 Kinase Kd 7.28 CHEMBL
Death-associated protein kinase 1 Kinase Kd 7.14 CHEMBL
Uncharacterized serine/threonine-protein kinase SBK3 Kinase Kd 5.24 CHEMBL
Death-associated protein kinase 3 Kinase Kd 7.05 CHEMBL
Serine/threonine-protein kinase PAK 4 Kinase Kd 5.80 CHEMBL
Serine/threonine-protein kinase DCLK3 Kinase Kd 6.59 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1A Kinase Kd 6.04 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 6.72 CHEMBL
Myotonin-protein kinase Kinase Kd 5.46 CHEMBL
Leukocyte tyrosine kinase receptor Kinase Kd 6.36 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 6.57 CHEMBL
Serine/threonine-protein kinase PLK3 Kinase Kd 6.15 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 6.44 CHEMBL
NUAK family SNF1-like kinase 2 Kinase Kd 6.49 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2 Kinase Kd 5.40 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4 Kinase Kd 5.74 CHEMBL
SRSF protein kinase 3 Kinase Kd 5.48 CHEMBL
Serine/threonine-protein kinase VRK2 Kinase Kd 5.40 CHEMBL
ALK tyrosine kinase receptor Kinase Kd 5.82 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 6.82 CHEMBL
Serine/threonine-protein kinase RIO1 Kinase Kd 5.60 CHEMBL
Serine/threonine-protein kinase RIO2 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase ULK1 Kinase Kd 6.52 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit delta Kinase Kd 7.05 CHEMBL
cGMP-dependent protein kinase 2 Kinase Kd 6.16 CHEMBL
Receptor-interacting serine/threonine-protein kinase 4 Kinase Kd 5.68 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1 Kinase Kd 5.72 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 5.70 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 5.96 CHEMBL
Serine/threonine-protein kinase PknB Kinase Kd 5.38 CHEMBL

External reference:

IDSource
4031235 VUID
N0000184017 NUI
C2931926 UMLSCUI
D09959 KEGG_DRUG
436LRU32H5 UNII
1092939-17-7 SECONDARY_CAS_RN
703779004 SNOMEDCT_US
1193326 RXNORM
014040 NDDF
28206 MMSL
d07812 MMSL
4031235 VANDF
702806008 SNOMEDCT_US
9287 INN_ID
RXT PDB_CHEM_ID
DB08877 DRUGBANK_ID
CHEBI:66919 CHEBI
C540383 MESH_SUPPLEMENTAL_RECORD_UI
CHEMBL1789941 ChEMBL_ID
CHEMBL1795071 ChEMBL_ID
25126798 PUBCHEM_CID
5688 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
JAKAFI HUMAN PRESCRIPTION DRUG LABEL 1 50881-005 TABLET 5 mg ORAL NDA 18 sections
JAKAFI HUMAN PRESCRIPTION DRUG LABEL 1 50881-010 TABLET 10 mg ORAL NDA 18 sections
JAKAFI HUMAN PRESCRIPTION DRUG LABEL 1 50881-015 TABLET 15 mg ORAL NDA 18 sections
JAKAFI HUMAN PRESCRIPTION DRUG LABEL 1 50881-020 TABLET 20 mg ORAL NDA 18 sections
JAKAFI HUMAN PRESCRIPTION DRUG LABEL 1 50881-025 TABLET 25 mg ORAL NDA 18 sections